A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 2908-2917

  Giles, Francis J ^a,c   Thomas, Deborah ^a   Garcia Manero, Guillermo ^a   Faderl, Stefan ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a   Ferrajoli, Alessandra ^a   Jeha, Sima ^a   Beran, Miloslav ^a   Koller, Charles ^a   Andreeff, Michael ^a   Cahill, Ann ^b   Clairmont, Caroline ^b   Sznol, Mario ^b   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Vion Pharmaceuticals Incorporated   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; HYDRAZINE DERIVATIVE; SULFONYLHYDRAZINE ALKYLATING AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; VNP 40101M;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; BONE PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; COLITIS; CONJUNCTIVITIS; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; EMPYEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GRAM NEGATIVE BACTERIUM; GRIP STRENGTH; HEADACHE; HUMAN; HYPOTENSION; INFUSION; INTESTINE OBSTRUCTION; LEUKEMIA; LEUKEMIA REMISSION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPENIC COLITIS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS; PYREXIA IDIOPATHICA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEPSIS; SHOULDER PAIN; SIDE EFFECT; SOFT TISSUE INFECTION; STOMATITIS; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERTIGO;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; AREA UNDER CURVE; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NAUSEA; SULFONAMIDES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 2442424121     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0738     Document Type: Article

References (33)

1. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2002;73-110.
2. Giles FJ. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt.) 2002;16:23-9.
3. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia Cancer (Phila.) 2003;98: 2095-104.
4. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. In press 2003.
5. O'Brien S, Giles FJ. Monoclonal antibodies in the treatment of lymphoid leukemia. Drugs Today (Barc.) 2003;39:541-50.
6. Cortes J, Estey E, Beran M, et al. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 2000;36:479-84.
7. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992;6:163-73.
8. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992;31:205-13.
9. Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994;318:205-26.
10. Lind MJ, Ardiet C. Pharmacokinetics of alkylating agents. Cancer Surv 1993;17:157-88.
11. Shyam K, Cosby LA, Sartorelli AC. Synthesis and evaluation of N,N′-bis(arylsulfonyl)hydrazines as antineoplastic agents. J Med Chem 1985;28:525-7.
12. Shyam K, Furubayashi R, Hrubiec RT, Cosby LA, Sartorelli AC. 1,2-Bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity. J Med Chem 1986;29:1323-5.
13. Shyam K, Hrubiec RT, Furubayashi R, Cosby LA, Sartorelli AC. 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity. J Med Chem 1987;30:2157-61.
14. Shyam K, Penketh PG, Divo AA, Loomis RH, Rose WC, Sartorelli AC. Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazines as antineoplastic agents. J Med Chem 1993;36: 3496-502.
15. Shyam K, Penketh PG, Loomis RH, Rose WC, Sartorelli AC. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. J Med Chem 1996;39:796-801.
16. Pratviel G, Shyam K, Sartorelli AC. Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer-phenotype. Cancer Biochem Biophys 1989;10:365-75.
17. Penketh PG, Shyam K, Sartorelli AC. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 2000;59:283-91.
18. Finch RA, Shyam K, Penketh PG, Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 2001;61:3033-8.
19. Briscoe WT, Duarte SP. Preferential alkylation by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) of guanines with guanines as neighboring bases in DNA. Biochem Pharmacol 1988;37:1061-6.
20. Lown JW, McLaughlin LW. Nitrosourea-induced DNA single-strand breaks. Biochem Pharmacol 1979;28:1631-8.
21. Mao J, Xu Y, Wu D, Almassian B. Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat. AAPS PharmSci 2002;4:24.
22. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
23. Gerson SL, Trey JE. Modulation of nitrosourea resistance in myeloid leukemias. Blood 1988;71:1487-94.
24. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 1995;6: 389-93.
25. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999;59:2402-10.
26. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000;6:3025-31.
27. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002;20:3249-53.
28. 6-alkylguanine-DNA-alkyl-transferase. Clin Cancer Res 2001;7:2309-17.
29. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996;56:5375-9.
30. 6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas Anticancer Drugs 1992;3:401-5.
31. Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91.
32. Xu Z, Chen ZP, Malapetsa A, et al. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002;13:511-9.
33. Chen ZP, Remack J, Brent TP, Mohr G, Panasci LC. Extraneuronal monoamine transporter expression and DNA repair vis-a-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Clin Cancer Res 1999;5:4186-90.